Myeloproliferative disorder
Information
- Disease name
- Myeloproliferative disorder
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06246006 | Active, not recruiting | Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative Neoplasia | October 1, 2023 | April 2025 | |
| NCT03434730 | Active, not recruiting | Phase 2 | Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation | February 7, 2018 | February 7, 2025 |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT04473911 | Active, not recruiting | Phase 1 | Haplo Peripheral Blood Sct In GVHD Prevention | August 14, 2020 | October 2024 |
| NCT00588666 | Completed | Phase 2 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | May 2006 | December 2011 |
| NCT00687414 | Completed | Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders | April 2008 | January 2010 | |
| NCT00909467 | Completed | Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases | April 2009 | November 2011 | |
| NCT01499147 | Completed | N/A | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | February 2000 | May 2013 |
| NCT01866839 | Completed | Phase 1/Phase 2 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | May 29, 2013 | June 28, 2018 |
| NCT03149055 | Completed | Phase 2 | Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) | May 4, 2017 | November 8, 2021 |
| NCT00175838 | Completed | N/A | Primary Thrombocythaemia 1 Trial | July 1997 | November 2016 |
| NCT03907436 | Completed | N/A | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | October 1, 2018 | October 1, 2019 |
| NCT00533923 | Completed | Phase 2 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | December 2002 | January 2007 |
| NCT00539695 | Completed | Phase 2 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | June 2007 | March 2014 |
| NCT00683046 | Completed | Phase 2 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | November 2001 | December 2014 |
| NCT03688490 | Completed | Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms | July 17, 2013 | November 4, 2013 | |
| NCT03734601 | Completed | Phase 2 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | November 5, 2018 | November 17, 2020 |
| NCT05884333 | Recruiting | Phase 2 | Cord Blood Transplant in Adults With Blood Cancers | May 22, 2023 | May 22, 2028 |
| NCT03852407 | Recruiting | Phase 2 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | February 4, 2019 | November 1, 2038 |
| NCT03869476 | Recruiting | N/A | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. | July 30, 2019 | January 30, 2024 |
| NCT03808805 | Unknown status | Phase 3 | Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms | April 16, 2019 | January 1, 2022 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0005547